Evaluating Technologies Found Cost Effective at Zero Price

This article explains why some technologies may fail to demonstrate cost effectiveness even when the acquisition price is set to zero, raising both methodological and ethical questions for health technology assessment (HTA) agencies. Learn more here. (Source: Sarah Davis, Dr. Ron Akehurst, Health Policy)

You might also be interested in:

AAM President Holds Firm Stance Against Recent Trade Deals November 4, 2018
HTA in Europe: Key Success Factors for Positive HTA Recommendations June 21, 2018
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
ISPOR Publication Synthesizes ‘Good Practices’ in HTA January 28, 2019
Real World Data Capabilities: Benchmarking Pharma Companies October 30, 2018
Looking at Some Key Takeaways From Anthem-Aspire Acquisition July 2, 2018
Article: Plans to Reduce Drug Prices Could Limit Treatments to… October 30, 2018